Cardiff Oncology Inc CRDF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CRDF is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $2.37
- Day Range
- $2.32–2.43
- 52-Week Range
- $0.94–6.42
- Bid/Ask
- $2.31 / $2.35
- Market Cap
- $104.69 Mil
- Volume/Avg
- 418,426 / 664,959
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 171.39
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 32
- Website
- https://www.cardiffoncology.com
Comparables
Valuation
|
Metric
|
CRDF
|
ITOS
|
CLDX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.72 | 1.14 | 3.50 |
Price/Sales | 171.39 | — | 376.93 |
Price/Cash Flow | — | — | — |
Price/Earnings
CRDF
ITOS
CLDX
Financial Strength
|
Metric
|
CRDF
|
ITOS
|
CLDX
|
|---|---|---|---|
Quick Ratio | 5.71 | 12.80 | 31.44 |
Current Ratio | 5.91 | 13.51 | 31.77 |
Interest Coverage | — | — | — |
Quick Ratio
CRDF
ITOS
CLDX
Profitability
|
Metric
|
CRDF
|
ITOS
|
CLDX
|
|---|---|---|---|
Return on Assets (Normalized) | −39.79% | −16.56% | −23.59% |
Return on Equity (Normalized) | −45.54% | −18.86% | −25.21% |
Return on Invested Capital (Normalized) | −49.27% | −22.78% | −25.04% |
Return on Assets
CRDF
ITOS
CLDX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Mlnvdmfrhv | Rpr | $565.6 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Dpjcjsq | Vjtmvz | $127.8 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Flzsnryr | Cwgkjyh | $118.7 Bil | |||
| Moderna Inc
MRNA
| Vkrzdrlm | Mdk | $46.8 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Mpbgjspq | Qzsvzf | $29.7 Bil | |||
| argenx SE ADR
ARGX
| Lypglgf | Hzr | $29.3 Bil | |||
| BioNTech SE ADR
BNTX
| Zhdrvcr | Cpgz | $20.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Mmtbfzv | Nvydvx | $16.1 Bil | |||
| United Therapeutics Corp
UTHR
| Trlfvwbws | Hsf | $15.0 Bil | |||
| Incyte Corp
INCY
| Yjfxnwt | Mgmvt | $13.5 Bil |